

5.5.3 s. 47G(1)(a)

Product	Quantity
s. 47G(1)(a)	

5.5.4 Stock received

s. 47G(1)(a)			
9	e s. 47G(1)(a)	e s. 47G(1)(a)	e s. 47G(1)(a)

6 PRE-VACCINATION AND DELIVERY

6.1 Pre-vaccination day

IHMS will send the local team a s. 47G(1)(a) s. 47G(1)(a)

. The purpose of this s. 47G(1)(a)

IHMS COVID-19 Vaccination	Implementation Plan	V3.00 DRAFT	5 Aug 2021
---------------------------	---------------------	-------------	------------

Released by Department of Home Affairs





6.2.3 s. 47G(1)(a)

Role	Specific job actions
s. 47G(1)(a)	s. 47G(1)(a)
s. 47G(1)(a)	• Assist with the s. 47G(1)(a) s. 47G(1)(a)

6.3 Facility layout and flow

The following s. 47G(1)(a) will be s. 47G(1)(a)

Area	Description
Waiting area	Large space with social distancing cues. Crowd management, enforcing physical distancing and security will be enforced in this area.
s. 47G(1)(a)	tment of Home
Vaccination area	Multiple stations with nursing staff allocated to each station.
Emergency management area	Set up for managing adverse events and high-risk recipients. Staff will not have access to systems such as emergency call buttons. The site will have clear instructions as to how to call for emergency assistance and ERV where required accesses and the total structure of the total structure of the total structure.
Post vaccination waiting area	All vaccine recipients must be observed for a minimum of 15 minutes post- vaccination. This is to ensure that people have access to appropriate care if they



Area	Description
	experience syncope, a significant immediate allergic reaction or other adverse event following vaccination.

A standardised screening process prior to entry to the clinic to exclude persons who display any symptoms of COVID–19 disease. Detainees will enter clinic, complete pre vaccine questionnaire and then shall be administered vaccine if nil contraindications noted. Detainees will then be given a "vaccine timecard" and ask to wait in the post vaccination monitoring area. After 15 minutes, shall be able to return to their compound if nil adverse reactions.

6.4 Detainee preparation

The IHMS s. 47G(1)(a)	
s. 47G(1)(a)	
	by Department of Home Affairs Freedom of Information Act 1982
6.5 Delivery	ment of Info
6.5.1 s. 47G(1)(a)	part om
Deliveries will s. 47G(1)(a) s. 47G(1)(a)	
s. 47G(1)(a) Key principles:	the
s. 47G(1)(a)	Released under the



- Following transport to clinic area and set up s. 47G(1)(a) • s. 47G(1)(a)
- s. 47G(1)(a) . s. 47G(1)(a)
- Vaccines received will s. 47G(1)(a) s. 47G(1)(a)

s. 47G

The following steps will be completed for all orders received:

Step #	Description	s. 47G(1)(a)
1	Receive consignment at Detention Facility • S. 47G(1)(a)	
2	Receive acceptance form from IHMS • s. 47G(1)(a) will be reviewed by the s. s. 47G(1)(a) • The s. 47G(1)(a) s. 47G(1)(a)	IHMS s. 7G(1) 7G(1) 7G(1) 7G(1) 7G(1) 7G(1) 7G(1)
6.6 \$	Storage	Released by Department of Home Aff.











- The responsible person will s. 47G(1)(a) s. 47G(1)(a)
- If required, s. 47G(1)(a)
 s. 47G(1)(a)

6.9 Approach to s. 47G(1)(a)

s. 47G(1)(a) can occur for many different reasons

s. 47G(1)(a)

To ensure early access to safe and effective COVID-19 vaccines, all s. 47G(1)(a)

will s. 47G(1)(a)

s. 47G(1)(a)

6.10	Dose	administr	ation po	olicy a	and	quidance
	2000	Ganning	ation pr	July .		galaalioo

IHMS will s. 47G(1)(a) s. 47G(1)(a)

S.

7.1 Patient pre-screening

s. 47G(1)(a)

1982

of Information Act

E

Freedor

the

under

Released by Department of Home Affairs



s. 7 IHMS staffs. 47G(1)(a) s. 47G(1)(a)

7.2 Approach s. 47G(1)(a)

 We will s. 47G(1)(a)
 so that the solution being provided is appropriate for their needs. IHMS will then s. 47G(1)(a)

7.2.1 Cultural responsiveness

IHMS s. 47G(1)(a)

s. 47G(1)(a)

Where there are persons identified at a facility that may require s. 47G(1)(a)

s. 47G(1)(a)

11

	me Affairs ion Act 1982
The designation of the s. 47G(1)(a) Will s. 47G(1)(a)	f Ho mat
7.2.3 s. 47G(1)(a) services	nt o
Where IHMS is required to arrange s. 47G(1)(a) s. 47G(1)(a)	by Departmer
	Released b under the <i>H</i>



7.3 Equipment required

7.3.1 General equipment required

s. 47G(1)(a)

7.3.3 Emergency equipment

s. 47G(1)(a)	
7.4 s. 47G(1) vaccine s. 47G(1)(a) After dilution, vials of s. 47G(1)(a) s. 47G(1)(a)	by Department of Home Affairs Freedom of Information Act 1982
Where a vaccine is prepared and administered by the same s. 47G(1)(a)	by D Free
s. 47G(1)(a)	Released under the









Released by Department of Home Affairs under the Freedom of Information Act 1982





















			artment of Home Affairs m of Information Act 1982
Emergency/anaphylaxis management	s. 47G(1)(a)	IHMS	Released by Dep under the Freedo



Item	Description / Action	Responsible
	s. 47G(1)(a)	
Detainee monitoring post vaccination	s. 47G(1)(a)	IHMS
(following the initial 15- 30 mins following vaccination)		

9.2 Anaphylaxis management

s. 47G(1)(a)	Department of Home Affairs
Anaphylaxis will be managed according to s. 47G(1)(a)	, Depar
	y D
	Released by under the Fre



9.3 AIR reporting requirements

IHMS will s. 47G(1)(a)

s. 47G(1)(a)

9.4 Clinical handover

IHMS will s. 47G(1)(a) s. 47G(1)(a)

Handover is attended by relevant members of the clinical team who:

s. 47G(1)(a)

The following principles will apply to handovers:

s. 47G(1)(a)

9.5 Second dose follow up

The second dose will be scheduled with the Detainee s. 47G(1)(a)This will allow the planning for the following:

- Detainees who may be out of the facility / transferred
- Staff not available/on leave

Where possible and to align with the COVID-19 Vaccine s. 47G(1)(a) s. 47G(1)(a)



9.6 s. 47G(1)(a)

s. 47G(1)(a)		

In line with advice from the Department and relevant stakeholders IHMS will work in partnership with the s. 47G(1)(a) s. 47G(1)(a) to identify s. 47G(1)(a)

10 PROGRAM MANAGEMENT

10.1 Regular meetings with stakeholders

Meeting	Description	Membership
Bi Weekly (national teams)	Review of project timelines, site planning, delivery schedules, communications, risks and opportunities.	IHMS, ABF/Home Affairs, FDSP
Weekly stakeholder (sites)	Review of project timelines, site planning, delivery schedules, communications, risks and opportunities, individual Detainee issues.	IHMS HSM, TL, Project Manager FDSP GM, Residential manager, T&E ABF/Home Affairs
10.2 Reporting 5. 47G(1)(a)		by Department Freedom of Int
. 47G(1)(a)		eleased ider the



IHMS Internal Use Only



Report	Description	Format
s. 47G(1)(a)		

10.3 Escalation protocol

All escalations in the first instance are to be sent to the below email address. This includes reporting issues, adverse events and temperature deviations:

COVID19VaccineOperationsCentre@Health.gov.au

Escalations to the Department of Home Affairs/ABF will be sent to the regional Superintendent, DCMA, HIDO and the Clinical team, as appropriate.



11 ENFORCEMENT AND REPORTING BREACHES

Breaches of this Procedure will s. 47G(1)(a)

All employees are expected to promptly and s. 47G(1)(a)



	IHMS	Document version history		Guidelin	Guideline		
Revision History							
Revision	Rev. Date	Description	Prepared by	Reviewed by	Date	Approved by	Date
1.00	05/07/2021	New Document	Operations Director, MS Pacific	Operations Manager, MS Pacific; Medical Director, Pacific MS, Commercial Director Pacific MS.	05/07/2021	DRAFT	
2.00	02/08/2021	Updated Document	Operations Director, MS Pacific	Operations Manager, MS Pacific; Medical Director, Pacific MS, Commercial Director Pacific MS.	02/08/2021	DRAFT	
3.00	05/08/2021	Working Document	Operations Director, MS Pacific	Operations Manager, MS Pacific; Medical Director, Pacific MS, Commercial Director Pacific MS, GM IHMS	05/08/2021	 General Manager IHMS; and Operations Director, MS Pacific 	05/08/202

Responsibilities

It is the responsibility of all IHMS staff working in the location to be familiar with this document. It is the responsibility of all IHMS Managers to ensure staff and have read and understand this document.

Abbreviations and Definitions

References and Attachments

© 2021 All copyright in these materials are reserved to International Health and Medical Services Pty Ltd. No text contained in these materials may be reproduced, duplicated or copied by any means or in any form, in whole or in part, without the prior written permission of International Health and Medical Services Pty Ltd.